INmune Bio's INKmune Demonstrates Excellent Safety And Increased NK-Cell Activity In First Dosing Cohort Of Phase I/II Trial For Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Portfolio Pulse from Benzinga Newsdesk
INmune Bio's INKmune has shown excellent safety and increased NK-cell activity in the first dosing cohort of its Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC).
September 26, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio's INKmune demonstrated excellent safety and increased NK-cell activity in the first dosing cohort of its Phase I/II trial for mCRPC, which could positively impact the company's stock price.
The positive safety and efficacy results from the INKmune trial are likely to boost investor confidence in INmune Bio, potentially leading to a short-term increase in stock price. The trial's success is crucial for the company's product pipeline and future revenue potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100